Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AstraZeneca NSD2-PWWP1 compound 34
- Development stage
- Unknown
- Lead developer
- AstraZeneca
01
Overview
AstraZeneca NSD2-PWWP1 compound 34: sourced facts only. name: "Through these activities, we have identified the most potent NSD2-PWWP1 binder reported so far in the literature: compound 34 (pIC50 = 8.2)." [PMID:38748070]; target: "Through these activities, we have identified the most potent NSD2-PWWP1 binder reported so far in the literature: compound 34 (pIC50 = 8.2)." [PMID:38748070]; developer: "Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K." [PMID:38748070]
02
Targets
NSD2 (Histone-lysine N-methyltransferase NSD2)
Beyond the preview
Go deeper on AstraZeneca NSD2-PWWP1 compound 34.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AstraZeneca NSD2-PWWP1 compound 34.